just ignore what is happening in the stock market for a while now. The ride is going to be very very choppy and very hard to predict entry points. this applies to all biotech stocks and not curis specific. good luck to all longs here and elsewhere.
This is a small biotech, not GE; it is news driven. See Barron's article dated August 12th: "Curis: Multiple candidates with data in 2015 and 2016.
• CUDC-907 should have Phase Ib data around ASH and begin a pivotal study in r/r DLBCL by YE:15 as well. Oral checkpoint inhibitor program should begin with anti-PD-L1 entering Phase I by YE:15 and providing an update in 2016 (similar for IRAK4 kinase inhibitor."
The Street is pro forma boilerplate analysis having nothing to do with small biotech. On the other hand, if Curis does not deliver on CUDC-907, then it's a failure having already thrown in the towel on CUDC-427. The Aurigene collaboration is too speculative even for me. If you have shorted it, congrats; but watch out if news is positive on 907, it should bounce back over $3.
beg to differ
Curis Inc - CRIS - EQUITY
Reviewed By: TheStreet Ratings on October 01, 2015.
Report Summary: TheStreet Ratings team rates Curis Inc as a Sell with a ratings score of D.
Report Snippet: We rate CURIS INC (CRIS) a SELL. This is driven by several weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.
Rating: 2.00 out of 5, 'D' Sell.
You can view the full analysis from the report here:
CRIS Rating Report
CRIS Performance as of Prev. Close
View Other CRIS Stats
CRIS EPS Performance
Fattaey is not the problem; don't panic. According to Barron's,
October 6, 2015, 11:22 A.M. ET
Everything’s Bouncing…Except Biotech and Apple
Is this POS ever even going to break $2.00 again, please all I want is $2.00 again so I cal sell this POS
Fattaey is the Jimmy Carter of CEO's, bad!
since 7/23 when CRIS closed at $3.57 only news that has changed is delay of IND PD-L1 filing from last quarter of 2015 to first half of 2016; 907 P2 trial start date still expected by December. Baird September presentation showed 907 most effective target is follicular lymphoma that has transformed into DLBCL, i.e. (t-fl)DLBCL. Of 10 evaluable patients 4 had this sub-type and 1 was CR, 2 PR and 1 SD. Hopefully latter 3 patients continue to improve and around ASH Curis announces it is starting P2 and that it is registration-directed. Since 7/23 all development stage biotechs have taken a hit.
as you may not know, the biotechnology sector has been crushed for the last week and, in addition, investors have become risk-intolerant - a double whammy for CRIS. Nothing at CRIS has changed since it was at $3.50 in July except that it did announce at Baird presentation in September that it was pushing back the date for the IND Aurigene PK-1 until first half of 2016. It did keep to its commitment to proceeding to P2 regarding CUDC- 907 by end of year, and hopefully that development will turn this stock around especially if it a pivotal phase. Until it shows strong likelihood of getting 907 to market Curis is going nowhere.
Right...... Piper wants you to buy so they can get out of the position without taking a huge loss.
I don't know who su(ks worse, our government officials who can barely govern themselves let alone a country,
Curis's CEO Fattaery or the s(h) it bags that recommend this stock
Not sure why my prior post was deleted. In any event, I noted that Curis is scheduled to present at the BIO Investor Conference on Oct. 20-21st in San Francisco; it is due to be notified shortly of whether its abstract submission to ASH has been accepted; its third quarter earnings conference should take place in early November, and then ASH starts on December 3rd. Will CRIS be proceeding to phase 2 regarding CUDC-907 by the end of the year? I hope so because this stock could sure use some buyers.